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Abstract	  
RNA	  transcripts	  of	  the	  B7	  family	  molecule	  (CD80)	  are	  diminished	  in	  blood	  leukocytes	  from	  animals	  clinically	  
affected	   with	   Visna/Maedi	   virus	   (VMV)	   infection.	   This	   work	   investigates	   whether	   the	   use	   of	   B7	   genes	  
enhances	  immune	  responses	  and	  protection	  in	  immunization-­‐challenge	  approaches.	  Sheep	  were	  primed	  by	  
particle-­‐mediated	   epidermal	   bombardment	  with	   VMV	   gag	   and	   env	   gene	   recombinant	   plasmids	   together	  
with	  plasmids	  encoding	  both	  CD80	  and	  CD86	  or	  CD80	  alone,	  boosted	  with	  gag	  and	  env	  gene	  recombinant	  
modified	  vaccinia	  Ankara	  virus	  and	  challenged	  intratracheally	  with	  VMV.	  Immunization	  in	  the	  presence	  of	  
one	  or	  both	  of	  the	  B7	  genes	  resulted	   in	  CD4+	  T	  cell	  activation	  and	  antibody	  production	  (before	  and	  after	  
challenge,	  respectively),	  but	  only	  immunization	  with	  CD80	  and	  CD86	  genes	  together,	  and	  not	  CD80	  alone,	  
resulted	   in	   a	   reduced	  number	   of	   infected	   animals	   and	   increased	   early	   transient	   cytotoxic	   T	   lymphocytes	  
(CTL)	  responses.	  Post-­‐mortem	  analysis	  showed	  an	  immune	  activation	  of	  lymphoid	  tissue	  in	  challenge-­‐target	  
organs	  in	  those	  animals	  that	  had	  received	  B7	  genes	  compared	  to	  unvaccinated	  animals.	  Thus,	  the	  inclusion	  
of	  B7	  genes	  helped	  to	  enhance	  early	  cellular	  responses	  and	  protection	  (diminished	  proportion	  of	  infected	  
animals)	  against	  VMV	  infection.	  
Keywords	  Sheep;	  Small	  ruminant	  lentivirus;	  DNA	  vaccination;	  B7	  costimulatory	  molecules	  
1.	  Introduction	  
Small	  ruminant	  lentiviruses	  (SRLV)	  include	  Visna/Maedi	  Virus	  (VMV)	  and	  caprine	  arthritis-­‐encephalitis	  virus	  
(CAEV).	  SRLV	  infect	  the	  monocyte/macrophage	  lineage	  in	  sheep	  and	  goats	  and	  cause	  chronic	  inflammatory	  
lesions	  in	  the	  lung,	  carpal	  joints,	  mammary	  glands,	  and	  brain	  in	  these	  ruminant	  species	  [1].	  SRLV	  are	  widely	  
spread	  and	  strategies	  based	  on	  early	  diagnosis,	  management	  and	  culling	  of	  seropositive	  animals	  have	  been	  
applied	   in	  order	  to	  eradicate	   infection.	   In	  natural	  SRLV	   infections	  of	  small	  ruminants,	  the	  response	  of	  the	  
immune	   system	   to	   virus	   in	   tissues	  may	   lead	   to	  pathology	   [2],	   [3],	   [4],	   [5]	   and	   [6],	  which	  may	   increase	   in	  
heavily	  infected	  animals	  [2],	  [7]	  and	  [8]	  till	  the	  animal's	  death.	  Although	  vaccination	  may	  prevent	  infection,	  
minimize	   clinical	   symptoms	  or	  delay	   the	  onset	  of	  disease	   resulting	   in	   an	   improvement	  of	   animal	  welfare	  
and	   avoidance	   of	   production	   losses	   (reviewed	   in	   Ref.	   [9]),	   efficient	   immunoprophylactic	   tools	   have	   not	  
been	  developed	  against	  SRLV	  and	  immunization	  has	  not	  conferred	  sterilizing	  immunity	  so	  far.	  
DNA	   vaccination	   is	   an	   alternative	   approach	   to	   conventional	   vaccines,	   triggering	   both	   antibody	   and	   cell-­‐
mediated	  immune	  responses	  [10].	  In	  goats,	  SRLV	  immunization	  with	  env	  plasmids	  has	  led	  to	  decreased	  viral	  
replication	  and	  load	  and	  diminished	  disease	  [11]	  whilst	  gag	  gene	  or	  peptide	  immunization	  has	  resulted	  in	  
enhancement	   of	   proviral	   load	   or	   disease	   [12]	   and	   [13].	   In	   sheep,	   immunization	  may	   lead	   to	   protection	  
against	  early	  lesion	  development	  or	  against	  viral	  infection	  (decreased	  load)	  [14],	  [15]	  and	  [16].	  Vaccination	  
with	  inactivated	  virus	  leads	  to	  disease	  [12],	  [17]	  and	  [18],	  but	  using	  an	  attenuated	  VMV	  clone	  results	   in	  a	  
diminished	  number	  of	  viral	  isolations	  after	  challenge	  [19].	  Mucosal	  immunization	  using	  plasmids	  containing	  
VMV	  env	  confers	  a	  protective	  effect	  seen	  by	  decreased	  proviral	  load	  [14]	  and	  [16],	  whilst	  the	  use	  of	  the	  gag	  
gene	  enhances	  protection	  against	   early	   lesion	  development	   [16].	  When	   the	   same	  plasmids	  are	  delivered	  
intradermally	  and	  this	  is	  followed	  by	  modified	  vaccinia	  Ankara	  virus	  (MVA)	  boosting,	  only	  the	  gag	  gene	  (or	  
gag	  in	  combination	  with	  env)	  gives	  rise	  to	  partial	  protection	  against	  infection	  [15],	  but	  when	  the	  vaccination	  
protocol	   is	  changed	  [20],	  pre-­‐existing	   immune	  responses	  to	  GAG	  proteins	  do	  not	  prevent	   infection.	  Thus,	  
immunization	  routes	  and	  viral	  genes	  used	  clearly	  affect	  the	  results	  of	  vaccination.	  
One	   of	   the	   limiting	   factors	   in	   DNA	   vaccination	   is	   antigen	   presentation	   after	   host-­‐cell	   transfection	   with	  
exogenous	  DNA	  [21].	  Full	  activation	  of	  T	  cells	  requires	  both	  an	  antigen-­‐specific	  stimulus	  provided	  by	  MHC–
peptide	  complex	  and	  a	  costimulatory	  signal	  [22]	  and	  [23].	  The	  engagement	  of	  CD28	  on	  the	  surface	  of	  T	  cells	  
by	  the	  costimulatory	  B7-­‐1	  (CD80)	  [24]	  and	  [25]	  or	  B7-­‐2	  (CD86)	  [26]	  and	  [27]	  molecules	  expressed	  by	  antigen	  
presenting	  cells	  (APCs)	  provides	  a	  potent	  costimulatory	  signal,	  leading	  to	  T	  cell	  proliferation,	  differentiation,	  
and	   cytokine	  production.	  However,	  CD80	  and	  CD86	  have	  higher	  affinity	   for	   the	  T	   cell	   inhibitory	   receptor	  
CTLA-­‐4	  than	  for	  CD28	  [28]	  and	  [29].	  This	  receptor	  is	  up-­‐regulated	  after	  T	  cell	  activation	  and	  it	  is	  suggested	  
that	  these	  interactions	  are	  important	  in	  helping	  to	  curb	  T	  cell	  responses.	  CD86	  exhibits	  faster	  dissociation	  
kinetics	  than	  CD80	  in	  interactions	  with	  both	  CD28	  and	  CTLA-­‐4	  [29].	  Also	  CD86	  is	  constitutively	  expressed	  on	  
B	   cells,	  monocytes	   and	   dendritic	   cells	  whilst	   CD80	   is	   inducible	   [23]	   and	   [26].	   Therefore,	   CD80	   and	   CD86	  
appear	  to	  have	  functional	  differences	  in	  T	  cell	  activation.	  
Ovine	  CD80	  [30]	  and	  CD86	  [31]	  genes	  have	  been	  identified	  recently.	  The	  mRNA	  levels	  of	  these	  molecules	  in	  
peripheral	  blood	  mononuclear	   cells	   (PBMC)	  have	  been	   studied	  at	  different	   stages	  of	   SRLV	   infection	   [32],	  
being	   increased	   in	   VMV-­‐infected	   asymptomatic	   sheep	   and	   associated	   with	   positive	   VMV-­‐specific	   T	   cell	  
proliferative	  responses.	  In	  contrast,	  low	  levels	  of	  these	  molecules	  (especially	  of	  CD80)	  are	  found	  in	  clinically	  
affected	  sheep,	  being	  associated	  with	  impairment	  of	  antigen-­‐specific	  cellular	  recall	  responses.	  
This	   study	   investigates	   the	   immune	   responses	   and	   degree	   of	   protection,	   against	   viral	   infection	   (load)	  
and/or	   immunity-­‐related	   lesion	   development,	   obtained	   by	   particle-­‐mediated	   epidermal	   delivery	   (PMED)	  
immunization	  of	   sheep	  against	  VMV,	  priming	  with	  plasmids	  encoding	  VMV	   (gag	  and	  env)	  genes	   together	  
with	  plasmids	  encoding	  B7	  genes	  (CD80	  and	  CD86)	  or	  CD80	  gene	  alone,	  and	  using	  a	  recombinant	  MVA	  for	  
booster	  immunization.	  
2.	  Materials	  and	  methods	  
2.1.	  Animals	  
Thirty	   castrated	   one-­‐year-­‐old	  males	   from	   a	   VMV-­‐free	   certified	   flock	   belonging	   to	   the	   Lleyn	   sheep	   breed	  
from	  the	  United	  Kingdom	  were	  used	  to	  avoid	  possible	  breed	  effects	  in	  comparisons	  with	  previous	  studies	  
involving	  similar	   immunization	  schemes.	  Absence	  of	  VMV	  infection	  was	  confirmed	  by	  a	  commercial	  ELISA	  
(Elitest	   MVV/CAEV,	   Hyphen	   Biomed)	   and	   PCR	   (as	   described	   below).	   The	   animal	   experiments	   were	  
performed	  following	  national	  regulations	  and	  institutional	  guidelines.	  
2.2.	  Plasmids	  and	  recombinant	  modified	  vaccinia	  virus	  Ankara	  used	  for	  immunization	  
Plasmids	  used	  for	  immunizations	  were	  derivates	  of	  pN3,	  generated	  from	  pEGFP-­‐N3	  (Clontech	  Laboratories	  
Inc.)	  by	  removing	  the	  EGFP	  gene,	  and	  which	  contains	  the	  eukaryotic	  HCMV	   immediate	  early	  promoter	  to	  
drive	  expression	  of	  the	  gene	  of	  interest.	  pN3	  was	  used	  as	  the	  control	  empty	  plasmid	  in	  immunizations	  and	  
also	  to	  make	  pN3-­‐gag	  and	  pN3-­‐env,	  which	  encode	  the	  VMV	  gag	  p55	  and	  env	  gp150	  genes	  (EV1	  strain,	  [33]	  
and	  [34])	  previously	  used	  in	  other	  vaccination	  studies	  [15]	  and	  [16].	  Large-­‐scale	  preparations	  of	  endotoxin-­‐
free	   plasmid	   DNA	   were	   made	   using	   a	   commercial	   maxi-­‐prep	   kit	   (Qiagen	   Ltd.)	   according	   to	   the	  
manufacturer's	   instructions.	   Expression	   of	   p55	   GAG	   and	   gp150	   ENV	   was	   determined	   by	   RT-­‐PCR	   and	  
Western	  blotting	  (WB)	  [16]	  and	  [34].	  
Ovine	  CD80	  (AY390555)	  and	  CD86	  (AY491977)	  cDNA,	  cloned	  into	  pGEM-­‐T	  easy	  plasmids	  [30]	  and	  [31],	  were	  
sub-­‐cloned	  into	  the	  eukaryotic	  expression	  plasmid	  pN3	  to	  produce	  pN3-­‐CD80	  and	  pN3-­‐CD86,	  respectively.	  
Expression	  of	  pN3-­‐CD80	  and	  pN3-­‐CD86	  was	  assessed	  by	  specific	  mRNA	  transcription	   in	   transfected	  ovine	  
skin	  fibroblasts	  using	  RT-­‐PCR	  using	  the	  following	  primers:	  forward	  SG80sFW	  5ʹ′-­‐CAT	  CAC	  CCC	  AAA	  GAG	  CGT	  
G-­‐3ʹ′	   and	   reverse	   B7-­‐1RV	   5ʹ′-­‐TGG	  AAA	  ACC	   TCC	  AGA	  GG-­‐3ʹ′	   to	   amplify	   a	   415	   nucleotide	   (nt)	   region	   of	   the	  
ovine	   CD80	   cDNA;	   and	   forward	   CD86-­‐TM-­‐FW	   5ʹ′-­‐GAC	   AAT	   CTT	   CTG	   TGT	   CCT	   GCA	   ACT	   TGA	   GCC-­‐3ʹ′	   and	  
reverse	  CD86-­‐2RV	  5ʹ′-­‐TCC	  AGG	  TTT	  TTG	  GAG	  TTC	  TAC	  CC-­‐3ʹ′	   to	  amplify	  a	  110	  nt	   region	  of	   the	  ovine	  CD86	  
cDNA.	  
Plasmid	   transfection	   was	   performed	   with	   Lipofectamine	   2000	   (Invitrogen)	   in	   monolayers	   of	   ovine	   skin	  
fibroblasts,	   as	   specified	   by	   the	   manufacturer.	   Transfected	   cells	   were	   incubated	   for	   48	   h	   and	   total	   RNA	  
extracted	  and	  analyzed	  by	  RT-­‐PCR	  for	  the	  presence	  of	  CD80	  or	  CD86	  RNA.	  Using	  the	  appropriate	  controls	  
(e.g.	  no	  RT,	  empty	  vector	   transfected	  cells)	  both	  the	  CD80	  and	  CD86	  expression	  plasmids	  were	  shown	  to	  
express	  the	  appropriate	  RNA	  (data	  not	  shown).	  MVA	  virus	  expressing	  either	  the	  gag	  p55	  (MVA-­‐gag)	  or	  the	  
env	  gp150	  (MVA-­‐env)	  genes	  of	  VMV	  EV1	  were	  used	  for	  immunization	  as	  described	  previously	  [16]	  and	  [34].	  
For	  the	  control	  group,	  immunization	  with	  recombinant	  MVA	  expressing	  β-­‐galactosidase	  (MVA-­‐pSC11)	  was	  
used.	  Viral	  protein	  expression	  was	  determined	  by	  WB	  using	  anti-­‐GAG	  and	  anti-­‐ENV	  specific	  rabbit	  sera	  [34].	  
2.3.	  Preparation	  of	  DNA-­‐coated	  gold	  particles	  for	  gene	  gun	  immunization	  
Gene	   gun	   parameters	   used	   for	   immunization	   were	   as	   previously	   described	   [15]	   and	   [35].	   Briefly,	   DNA	  
plasmids	  were	  precipitated	  onto	  gold	  particles	  (BioRad	  Laboratories	  Ltd.)	  resulting	  in	  a	  DNA	  loading	  ratio	  of	  
4	   μg/mg	   of	   gold.	   The	   mixture	   was	   allowed	   to	   precipitate,	   washed	   in	   dehydrated	   99.9%	   ethanol	   (VWR	  
International	   Ltd.)	   and	   then	   re-­‐suspended	   in	   ethanol	   containing	   polyvinylpyrrolidone.	   Each	   cartridge	  
contained	  approximately	  1	  μg	  of	  plasmid	  DNA.	  Delivery	  was	  performed	  intradermally	  using	  the	  Helios	  Gene	  
gun	   system	   (BioRad	   Laboratories	   Ltd.).	   The	   gene	   gun	  discharge	  pressure	  used	   to	   propel	   the	  DNA-­‐coated	  
gold	  particles	  into	  the	  dermal–epidermal	  junction	  was	  435	  psi.	  
2.4.	  Expression	  and	  purification	  of	  recombinant	  GAG	  proteins	  and	  mock	  protein	  preparations	  
Plasmids	   (pRSET)	  containing	  VMV	  strain	  EV1	  gag	  p14,	  p17	  and	  p25	   [36]	  were	  used	  once	  sequences	  were	  
verified.	  Recombinant	  p14,	  p17,	  p25	  and	  mock	  preparations	  were	  produced	  as	  described	  previously	  [16].	  
2.5.	  Immunization	  and	  challenge	  
Table	  1	  shows	  the	  immunization	  groups	  and	  number	  of	  animals	  used.	  All	  groups	  received	  a	  total	  of	  30	  μg	  of	  
DNA	  per	   animal	   by	   gene	   gun	   at	  weeks	   0	   and	   4	   (10	   μg	   of	   each	   plasmid	   except	   the	   gag–env–CD80–CD86	  
group	  that	  received	  10	  μg	  of	  each	  VMV	  plasmid	  and	  5	  μg	  each	  of	  the	  CD80	  and	  CD86	  plasmids).	  The	  same	  
sheep	  were	  boosted	  subcutaneously	  at	  week	  10	  with	  recombinant	  MVA-­‐gag	  and	  MVA-­‐env	  (108	  pfu	  each).	  
The	  control	  group	  received	  MVA-­‐pSC11	  (2	  ×	  108	  pfu).	  
	  Table	  1.	  
	  
	  	  	  	  
VMV	  strain	  EV1	  [33]	  grown	  and	  titrated	  as	  described	  previously	  [37]	  was	  used	  to	  challenge	  sheep	  with	  1	  ×	  
103	  TCID50	  in	  1	  ml	  of	  PBS	  12	  weeks	  after	  priming	  via	  the	  intratracheal	  route,	  as	  described	  elsewhere	  [38].	  
2.6.	  Sampling	  
Blood	  samples	  were	  collected	  before	  priming	  (hereafter	  called	  week	  0),	  after	  DNA	  priming	  (week	  7),	  after	  
recombinant	  MVA	   boosting	   but	   before	   challenge	   (week	   12),	   and	   after	   VMV	   challenge	   at	   different	   time	  
points	   (weeks	   16,	   20	   and	   24,	   that	   is	   weeks	   4,	   8	   and	   12	   post-­‐challenge).	   Sheep	   were	   euthanised	   and	  
necropsied	   25	   weeks	   after	   the	   start	   of	   the	   experiment	   (13	   weeks	   post-­‐challenge).	   Lung	   lobes	   and	  
mediastinal	  lymph	  node	  (MLN)	  samples	  were	  taken	  as	  previously	  described	  [15]	  and	  [16].	  
2.7.	  Measurement	  of	  anti-­‐VMV	  antibodies	  
The	  presence	  of	  VMV-­‐specific	  antibodies	  was	  assessed	  in	  serum	  after	  immunization	  and	  challenge	  using	  a	  
commercial	   VMV	   antibody	   ELISA	   test	   (Elitest®,	   from	   Hyphen	   Biomed,	   Neuville-­‐sur	   Oise,	   France)	   that	  
employs	  as	  plate	  coating	  VMV	  antigens	  a	  synthetic	  peptide	  of	   the	  ENV	  transmembrane	  protein	   (TM)	  and	  
recombinant	  GAG	  p25	  protein	  [39].	  Samples	  were	  analyzed	   in	  duplicate.	  The	  ELISA	  score	  (optical	  density,	  
O.D.	   ratio)	  was	   calculated	  as	   the	   ratio	  between	   the	  mean	  absorbance	   (A450)	  of	   a	   sample	   and	   the	  mean	  
absorbance	  of	  the	  kit	  controls	  (cut-­‐off),	  according	  to	  the	  manufacturer's	  instructions.	  ELISA	  scores	  ≥1	  were	  
considered	  positive.	  
An	  ELISA	  method	  using	  whole	  virus	  for	  coating	  (140	  ng	  per	  well)	  was	  applied	  as	  previously	  described	  [16].	  
The	  positivity	   threshold	  was	  established	   for	  each	  plate	  as	   the	  mean	  O.D.	  value	  of	  known	  negative	  serum	  
samples	  plus	  two	  times	  the	  standard	  deviation	  (mean	  +	  2S.D.).	  Dilution	  series	  of	  sera	  were	  started	  at	  1	  in	  
100.	   The	   reciprocal	   of	   the	   last	   positive	   serum	   dilution	  was	   taken	   as	   the	   antibody	   titre	   and	   results	  were	  
expressed	  as	  a	  box	  plot	  which	  includes	  the	  median	  value	  and	  the	  interquartile	  range.	  
Neutralizing	  antibody	  (NtAb)	  determinations	  were	  performed	  in	  six	  replicates	  (100	  TCID50	  virus	  per	  well)	  as	  
previously	  described	  [19]	  except	  that	  the	  incubation	  of	  the	  virus	  with	  serum	  at	  the	  different	  dilutions	  was	  
done	  for	  36	  h	  and	  the	  cells	  used	  for	  the	  assay	  were	  monolayers	  of	  GSM-­‐T	  β-­‐gal	  cultures	  (kindly	  supplied	  by	  
Dr.	  Valas,	  AFSSA,	  Niort,	  France).	  These	  cells	  were	  incubated	  with	  the	  mixture	  for	  10	  days,	  fixed	  and	  stained	  
with	  X-­‐gal.	  GSM-­‐T	  β-­‐gal	  cells	  are	  goat	  synovial	  membrane	  cells	  transfected	  and	  permanently	  expressing	  a	  β-­‐
galactosidase	   construct	   that	   contains	   a	   Rev	   Responsive	   Element	   (RRE)	   so	   that	   β-­‐galactosidase	   protein	   is	  
only	  expressed	  if	  Rev	  protein	  of	  the	  virus	  is	  present	  [40].	  Thus,	  the	  presence	  of	  the	  virus	  in	  the	  supernatant	  
was	   determined	   by	   blue	   staining	   due	   to	   the	   presence	   of	   the	   REV	   protein.	   NtAb	   titres	   of	   sera	   were	  
calculated	   as	   the	   reciprocal	   of	   the	   serum	   dilution	   that	   caused	   loss	   of	   infectivity	   in	   50%	   of	   inoculated	  
cultures.	  Control	  cultures	  were	  inoculated	  with	  virus	  in	  the	  absence	  of	  antiserum.	  
To	  detect	  antibody	  by	  WB,	  virus	  antigen	  was	  diluted	  with	  125	  μl	  of	  lysis	  buffer	  (0.05	  M	  Tris	  pH	  7.2,	  0.15	  M	  
NaCl,	   0.1%	   SDS,	   1%	   Triton	   X-­‐100,	   1%	  deoxycholate,	   1	  mM	  phenylmethyl-­‐sulfonyl	   fluoride)	   and	   125	  μl	   of	  
loading	   buffer	   (0.5	   M	   Tris	   HCl	   pH	   6.8,	   2%	   SDS,	   10%	   glycerol,	   0.1	   M	   dithiothreitol,	   bromophenol	   blue),	  
applied	  to	  a	  4%	  stacking	  gel	  and	  a	  12%	  gradient	  separation	  gel	  and	  blotted	  onto	  a	  nitrocellulose	  transfer	  
membrane	  after	  electrophoresis.	  Transfer	  was	  carried	  out	  at	  4	  °C	  for	  75	  min	  in	  0.25	  M	  Tris,	  1.92	  M	  glycine,	  
20%	  methanol	  and	  0.01%	  SDS,	  at	  100	  V	  and	  250	  mA.	  After	  transfer,	  the	  membrane	  was	  blocked	  for	  at	  least	  
1	  h	  at	  37	  °C	  with	  PBS	  containing	  0.2%	  Tween	  20	  (PBS-­‐T)	  and	  3%	  bovine	  serum	  albumin	  (BSA).	  After	  blocking,	  
the	  membrane	  was	  cut	   into	  strips	  and	   incubated	  with	  serum	  samples	  diluted	  1:100	   for	  1	  h	  at	  37	   °C	  with	  
shaking.	  Rabbit	  anti-­‐sheep	  IgG	  conjugated	  to	  peroxidase	  was	  used	  at	  a	  dilution	  of	  1:2000	  in	  PBS-­‐T	  with	  1%	  
BSA	   for	   1	   h	   at	   37	   °C	   and	   reactions	   were	   developed	   using	   Chemiluminescence	   (Amersham	   ECL	  Western	  
blotting	  detection	  reagents,	  GE	  Healthcare).	  
2.8.	  Measurement	  of	  anti-­‐VMV	  T	  cell	  reactivity	  
Heparinized	  blood	  was	  collected	  (10	  U/ml	  final)	  and	  PBMC	  isolated	  on	  a	  Ficoll-­‐Hypaque	  gradient	  (δ	  =	  1.077;	  
Lymphoprep,	   Axis-­‐Shield),	   then	   suspended	   in	   RPMI-­‐1640	   medium	   with	   25	   mM	   HEPES	   (Sigma–Aldrich	  
Company	  Ltd.),	  supplemented	  with	  2	  mM	  l-­‐glutamine,	  50	  μM	  beta-­‐mercaptoethanol,	  100	  U	  penicillin	  and	  
100	  μg	  streptomycin/ml,	  2.5	  μg	  amphotericin	  B/ml	  and	  10%	  foetal	  calf	  serum	  (FCS)	  (10%RPMI).	  
A	   cytotoxic	   assay	   was	   performed	   for	   the	   detection	   of	   precursor	   cytotoxic	   T	   lymphocytes	   (CTL).	   Animals	  
were	  deemed	  to	  show	  the	  presence	  of	  CTL	  if	  the	  percentage	  specific	  51Cr	  release	  from	  VMV	  infected	  minus	  
mock	  infected	  autologous	  cells	  was	  >10%	  above	  that	  from	  heterologous	  infected	  minus	  mock	  infected	  cells	  
[16],	  in	  which	  the	  killing	  of	  mock	  infected	  and	  heterologous	  cells	  was	  less	  than	  10%.	  The	  frequency	  of	  CTL-­‐
positive	  animals	  was	  used	  for	  analysis	  of	  results.	  VMV	  GAG-­‐specific	  T	  cell	  proliferative	  and	  CTL	  responses	  
were	  compared	  within	  and	  between	  groups	  throughout	  the	  experimental	  period	  using	  PBMC.	  
T	  cell	  proliferation	  assays	  were	  performed	  in	  quadruplicate	  as	  described	  elsewhere	  [16].	  Briefly,	  105	  PBMC	  
in	   10%	   RPMI	   were	  mixed	   with	   different	   dilutions	   of	   recombinant	   GAG	   proteins	   (from	   50	   μg/ml	   to	   6.25	  
μg/ml	   for	   p25	   and	   p14;	   and	   from	   25	   μg/ml	   to	   3.12	   μg/ml	   for	   p17).	   Positive	   Concanavalin	   A	   (ConA	   at	   5	  
μg/ml)	  and	  negative	  (mock	  antigen)	  controls	  were	  included.	  Cells	  were	  labelled	  with	  [3H]	  thymidine	  (0.037	  
MBq/well,	  GE	  Healthcare)	  and	  cellular	  proliferation	  assessed	  by	  measuring	   the	   incorporation	  of	   [3H]	   into	  
the	   cells	   (cpm).	   The	   stimulation	   index	   (S.I.)	  was	   calculated	   for	   each	  antigen	  using	   the	   formula	   S.I.	   =	   cpm	  
with	   antigen/cpm	  with	  mock	   antigen.	   Results	  were	   analyzed	   using	   the	  median	   stimulation	   indices	   of	   all	  
dilutions	   for	   each	   protein.	   An	   individual	   animal	   was	   considered	   to	   show	   positive	   T	   cell	   reactivity	   if	   the	  
stimulation	  index	  was	  greater	  than	  3.	  
2.9.	  Measurement	  of	  proviral	  load	  
2.9.1.	  Proviral	  load	  in	  blood	  
EDTA	  blood	  (8	  ml)	  was	  collected	  at	  each	  time	  point	  and	  PBMC	  isolated	  on	  a	  Ficoll-­‐Hypaque	  gradient	   (δ	  =	  
1.077;	   Lymphoprep,	  Axis-­‐Shield).	   Following	  erythrocyte	   lysis,	  genomic	  DNA	  was	  extracted	  with	  a	  QIAamp	  
DNA	   Blood	   Mini	   Kit	   (Qiagen	   Ltd.)	   according	   to	   the	   manufacturer's	   instructions.	   DNA	   was	   quantified	   by	  
spectrophotometry	  (Bio-­‐Rad	  SmartSpec	  Plus	  Spectrophotometer,	  Bio-­‐Rad)	  and	  a	  final	  concentration	  of	  100	  
ng/μl	  was	  used.	  Five	  microliters	  of	  freshly	  prepared	  DNA	  were	  used	  in	  a	  25	  μl	  real-­‐time	  PCR	  assay	  specific	  
for	  VMV	  gag	  p25.	  Gag	  amplicon	   length	  was	  106	  nt.	  Primers	  and	  probe	  sequences	  were	  as	   follows:	   sense	  
primer	   S2:	   5ʹ′-­‐TCAACAGGCATCACAGGCTAATA-­‐3ʹ′	   (nt.	   1249–1271);	   antisense	   primer	   AS2:	   5ʹ′-­‐
GTTACCTGGCCTATGCGACAT-­‐3ʹ′	   (nt.	  1334–1353);	  antisense	  probe:	  5ʹ′-­‐ACCGCTCTCAAGGCTGTTATGACCCA-­‐3ʹ′	  
(nt.	   1301–1325).	   Nucleotide	   positions	   refer	   to	   the	   published	   EV1	   strain	   sequence	   [33].	   A	   dual-­‐labelled	  
probe	  (Operon)	  was	  used	  with	  6-­‐FAM	  as	  the	  5ʹ′	  fluorophore	  and	  a	  3ʹ′	  Black	  Hole	  Quencher	  (BHQ1a-­‐Q).	  DNA	  
samples	  were	  tested	  three	  times	   in	   triplicate	   (nine	  replicates	   in	  all).	  Ten-­‐fold	  serial	  dilutions	  of	  a	  plasmid	  
(pDRIVE,	   Qiagen	   Ltd.)	   carrying	   a	   567	   bp	   EV1	   gag	   fragment	   (nt.	   963–1529)	   were	   used	   to	   generate	   the	  
standard	  curve.	  Plasmid	  copy	  numbers	  ranged	  from	  10	  to	  106	  per	  reaction.	  Positive	  and	  negative	  controls	  
were	  included	  in	  each	  assay.	  Reactions	  were	  carried	  out	  in	  an	  ABI	  7900	  system	  (Applied	  Biosystems),	  with	  
the	  following	  thermal	  profile:	  10	  min	  at	  95	  °C	  and	  then	  45	  cycles	  of	  95	  °C	  15	  s	  and	  60	  °C	  1	  min.	  
Mean	  copy	  number	  per	  reaction	  was	  converted	  to	  mean	  copy	  number	  per	  microgram	  of	  template	  DNA	  for	  
each	  animal.	  Animals	  which	  showed	  positive	  proviral	  load	  in	  at	  least	  one	  time	  point	  of	  the	  three	  time	  points	  
tested	  (weeks	  16,	  20	  and	  24)	  in	  the	  post-­‐challenge	  period,	  were	  considered	  infected.	  
2.9.2.	  Proviral	  load	  in	  tissues	  
One	  hundred	  milligrams	  of	  tissue	  from	  MLN	  and	  lung	  sections	  as	  for	  the	  pathological	  evaluation	  (four	  lobes	  
of	  the	  lung	  or	  the	  MLN,	  see	  below)	  were	  taken	  at	  necropsy	  and	  stored	  in	  RNA	  Later	  (Qiagen	  Ltd.)	  at	  −80	  °C.	  
Tissue	   samples	  were	  minced	  with	  a	   scalpel	  and	  homogenized	  with	  a	  pestle	   in	  680	  μl	  of	   lysis	  buffer	   (5	  M	  
NaCl,	  1	  M	  Tris–HCl	  pH	  8.5,	  0.5	  M	  EDTA,	  10%	  SDS).	  Following	  incubation	  with	  proteinase	  K	  at	  56	  °C,	  DNA	  was	  
extracted	  and	   the	  proviral	   copy	  number	  measured,	  as	  described	  above,	   from	  each	   lung	  piece	  and	   lymph	  
node.	  Mean	  copy	  number	  per	   reaction	  was	  converted	   to	  mean	  copy	  number	  per	  microgram	  of	   template	  
DNA	  for	  each	  animal.	  Animals	  were	  considered	  positive	  if	  the	  provirus	  was	  detected	  in	  at	  least	  one	  of	  the	  
tissue	  sections	  analyzed.	  
2.10.	  Pathology	  studies	  
Lungs	   were	   removed	   aseptically	   and	   studied	   first	   macroscopically	   for	   pathological	   changes	   (colour,	  
consistence,	  size	  and	  weight).	  Samples	  from	  four	  different	  lung	  lobes	  (the	  right	  accessory	  cranial	  lobe,	  the	  
right	   apical	  medial	   lobe,	   the	   right	   caudal	   lobe	  and	   the	   left	   cardiac	   cranial	   lobe)	  and	  MLN	  were	   taken	   for	  
histological	  studies.	  Tissues	  were	  fixed	  in	  10%	  phosphate-­‐buffered	  formalin	  (Sigma),	  embedded	  in	  paraffin	  
and	  sectioned	  according	  to	  standard	  procedures.	  Sections	  were	  stained	  with	  Hematoxylin–Eosin	  and	  scored	  
blind	  for	  pathology	  by	  two	  independent	  pathologists.	  
Histological	  changes	  in	  lung	  and	  MLN	  were	  scored:	  in	  the	  lung,	  lymphoid	  follicle	  hyperplasia	  and	  interstitial	  
pneumonia	   as	  well	   as	   bronchial	   associated	   lymphoid	   tissue	   hyperplasia	   and	   perivascular	   infiltrates	  were	  
scored	  on	  a	  scale	  of	  0–3;	  and	  in	  the	  MLN,	  lymphoid	  follicle	  reactivity	  and	  cortical	  hyperplasia	  were	  scored	  
on	  a	  scale	  of	  0–1.	  The	  mean	  of	  all	  scores	  was	  used	  for	  each	  animal.	  
2.11.	  Statistical	  analysis	  
Fisher's	   exact	   test	   was	   used	   for	   comparisons	   on	   frequency	   of	   individuals	   positive	   at	   each	   time	   point.	  
Between	  and	  within-­‐group	  comparisons	  of	  medians	  at	  each	  time	  point	  were	  done	  with	  Mann–Whitney	  and	  
Wilcoxon	  rank	  tests,	  respectively.	  Differences	  were	  considered	  significant	  if	  p	  ≤	  0.05.	  
3.	  Results	  
3.1.	  Cellular	  immune	  responses	  
3.1.1.	  Cytotoxic	  T	  lymphocyte	  response	  
Although	  CTL	  reactivity	  was	  generally	  low,	  differences	  in	  the	  proportion	  of	  CTL-­‐positive	  animals	  were	  found	  
among	  the	  study	  groups	  (Fig.	  1).	  In	  the	  control	  group,	  no	  evidence	  of	  CTL	  response	  was	  detected	  in	  the	  pre-­‐
challenge	  period	  (Fig.	  1A)	  and	  the	  percentage	  of	  positive	  animals	  in	  the	  post-­‐challenge	  period	  was	  similar	  to	  
that	   found	   in	   the	  groups	  receiving	  B7.	   In	   the	  gag–env	   immunized	  group,	  CTL	  activity	  was	   found	  after	   the	  
MVA	  boost	  (week	  12),	  resulting	  in	  over	  50%	  positive	  animals;	  but	  the	  highest	  activity	  was	  reached	  at	  week	  
20,	   with	   more	   than	   80%	   positive	   animals	   (	   Fig.	   1B).	   In	   this	   group,	   statistical	   differences	   were	   found	  
significant	   between	   the	   pre-­‐challenge	   (weeks	   0	   and	   7)	   and	   the	   post-­‐challenge	   (week	   20)	   periods.	   In	   the	  
gag–env–CD80	  group,	  CTL-­‐positive	  animals	  appeared	  at	  week	  7	  as	  a	  result	  of	  plasmid	  immunization	  in	  25%	  
of	  the	  animals	  (	  Fig.	  1C).	  This	  low	  proportion	  was	  maintained	  until	  week	  16.	  By	  the	  end	  of	  the	  experimental	  
period	  CTL	  activity	  decreased	  (12.5%	  positive	  animals)	  but	  did	  not	  disappear.	   In	  the	  gag–env–CD80–CD86	  
group,	  the	  highest	  proportion	  of	  CTL-­‐positive	  animals	  was	  reached	  early	  after	  immunization	  (week	  7,	  63%),	  
significantly	   increased	   compared	   to	   week	   0.	   The	   number	   of	   CTL-­‐positive	   animals	   decreased	   thereafter,	  
especially	  post-­‐challenge,	  until	  disappearing	  by	  the	  end	  of	  the	  experimental	  period	  (	  Fig.	  1D).	  
	  Fig.	  1.	  	  
	  	  	  	  CTL	  responses.	  The	  percentage	  of	  CTL-­‐positive	  animals	   in	  the	  control	  and	   immunization	  groups	   is	  shown.	  (*)	  Statistically	  significant	  differences	  
between	  weeks	  of	  the	  experimental	  period	  in	  the	  percentage	  of	  CTL-­‐positive	  animals	  according	  to	  Fisher's	  Exact	  test	  within	  each	  study	  group:	  in	  the	  
gag–env–CD80–CD86	  group,	  the	  percentage	  in	  week	  7	  was	  significantly	  higher	  (p	  =	  0.025)	  than	  in	  week	  0;	  and	  in	  the	  gag–env	  group	  the	  percentage	  
in	  week	  20	  was	  higher	  than	  in	  weeks	  0,	  7	  (p	  =	  0.004	  in	  both	  cases)	  and	  16	  (p	  =	  0.029).	  
A	   comparative	   analysis	   between	   groups	   revealed	   a	   significantly	   increased	   proportion	   of	   CTL-­‐positive	  
animals	  at	  week	  7	  in	  the	  gag–env–CD80–CD86	  group	  (63%)	  compared	  to	  control	  and	  gag–env	  groups	  (both	  
0%).	   In	   contrast,	  both	  B7	   immunized	  groups	  had	  significantly	  decreased	  numbers	  of	  CTL-­‐positive	  animals	  
compared	  to	  the	  gag–env	  group	  (12.5%	  in	  each	  B7	  group	  vs.	  85.7%	  in	  the	  gag–env	  group)	  at	  week	  20.	  
Overall	   these	   results	   indicate	   that	   inclusion	   of	   B7	   genes	   in	   gag–env	   immunization	   results	   in	   a	   transient	  
(week	  7)	  increase	  in	  the	  CTL	  response	  pre-­‐challenge	  (this	  increase	  being	  significant	  when	  both	  B7	  genes	  are	  
included	  in	  the	  inoculum)	  but	  a	  decreased	  CTL	  response	  post-­‐challenge.	  
3.1.2.	  T	  lymphocyte	  proliferative	  responses	  
3.1.2.1.	  Effect	  of	  plasmid	  immunization	  
PBMC	   from	   the	   animals	   under	   study	   were	   stimulated	   with	   GAG	   protein	   (p14,	   p17	   or	   p25)	   and	   S.I.	   of	  
proliferative	   responses	   determined	   (Fig.	   2).	   Comparatively,	   the	  p14	   and	  p25	  proteins	   frequently	   induced	  
the	   lowest	  and	   the	  highest	  S.I.,	   respectively.	  Within-­‐group	  analysis	   revealed	   that	  both	  groups	   immunized	  
with	  B7	  genes	  had	  a	  significantly	  increased	  (S.I.	  ≥	  3)	  early	  (week	  7)	  proliferative	  response	  against	  all	  of	  the	  
GAG	  proteins.	  Also,	  between	  group	  comparisons	   (	   Fig.	  2)	   indicated	   that	   the	  early	   response	   (week	  7)	  was	  
significantly	   increased	   in	   the	   CD80/CD86	   group	   compared	   to	   the	   control	   group	   when	   using	   p17	   as	  
stimulatory	  protein;	  and	  in	  both	  B7	  groups	  compared	  to	  the	  gag–env	  group	  using	  either	  p14	  or	  p25.	  
	  Fig.	  2.	  	  
	  	  	  	  T	  cell	  proliferative	  responses.	  The	  antigen	  stimulation	  indices	  (S.I.)	  in	  the	  different	  groups	  throughout	  the	  study	  period	  (weeks	  0–24)	  are	  shown,	  
using	  as	  stimulatory	  antigen	  p14,	  p17	  or	  p25	  GAG	  proteins.	  Results	  are	  expressed	  as	  box	  plots	  with	  the	  median	  of	  the	  group	  shown	  as	  a	  line	  and	  the	  
interquartile	  range	  represented	  by	  the	  box.	  (*)	  Shows	  values	  significantly	  higher	  (p	  <	  0.05)	  than	  the	  control	  group	  according	  to	  a	  Mann–Whitney	  
test,	  found:	  for	  p14,	  gag–env–CD80	  and	  gag–env–CD80–CD86	  groups	  at	  week	  16;	  for	  p17,	  gag–env–CD80	  group	  at	  weeks	  12	  and	  16;	  and	  gag–env–
CD80–CD86	  group	  at	  weeks	  7,	  12	  and	  16.	  (§)	  Significantly	  higher	  (p	  <	  0.05)	  than	  gag–env	  group,	  found:	  for	  p14,	  gag–env–CD80	  group	  at	  weeks	  7,	  12	  
and	  16;	  and	  gag–env–CD80–CD86	  group	  at	  week	  7;	   for	  p17,	  gag–env–CD80	  group	  at	  week	  12;	   for	  p25,	  gag–env–CD80	  and	  gag–env–CD80–CD86	  
groups	  at	  week	  7.	  See	  text	  for	  intra-­‐group	  differences	  between	  time	  points.	  
3.1.2.2.	  Effect	  of	  MVA	  booster	  immunization	  
In	  both	  B7	  immunized	  groups,	  boosting	  with	  recombinant	  MVA	  (week	  10)	  resulted,	  by	  week	  12,	  in	  a	  further	  
significant	   increase	   of	   the	   proliferative	   response	   compared	   to	   plasmid	   immunization	   (weeks	   0	   and	   7)	  
responses	  using	  either	  p17	  or	  p25	  as	  stimulatory	  antigens.	  Furthermore,	  within	  the	  gag–env	  group	   in	  the	  
absence	  of	  B7	  genes	   in	  the	   inoculum,	  the	  proliferative	  response	  was	  significantly	   increased	  only	  after	  the	  
MVA	  booster	   immunization	   (using	  p17	  and	  p25	  protein	   for	   stimulation,	   significance	  not	   indicated	  on	   the	  
graph).	   Analysis	   between	   groups	   (	   Fig.	   2)	   revealed	   that	   by	   week	   12	   animals	   receiving	   B7	   genes	   had	   a	  
significantly	  increased	  response	  compared	  to	  the	  control	  group	  using	  p17	  for	  stimulation.	  Finally,	  the	  gag–
env–CD80	  group	  had	  a	  significantly	  higher	  response	  than	  the	  gag–env	  group	  using	  either	  p14	  or	  p17.	  
3.1.2.3.	  Effect	  of	  VMV	  challenge	  
By	  week	  16,	   both	   groups	   receiving	  B7	  maintained	   the	  proliferative	   responses	   observed	  before	   challenge	  
(week	  12)	  and	  had	  significantly	  increased	  responses	  compared	  to	  the	  control	  group	  using	  p14	  or	  p17	  (	  Fig.	  
2).	  However,	   the	   control	   group	  had	  a	   significantly	   increased	   response	  when	   comparing	   in	   this	   group	   the	  
post-­‐challenge	  and	   the	  pre-­‐challenge	  periods	   (using	  p17	  and	  p25	  proteins,	  weeks	  20	  and	  24,	   significance	  
not	  indicated	  in	  the	  figure).	  Later	  post-­‐challenge	  time	  points	  (weeks	  20	  and	  24)	  showed	  similar	  responses	  in	  
the	  different	  study	  groups.	  
Overall,	  immunization	  including	  B7	  triggered	  an	  increased	  proliferative	  response	  to	  viral	  antigen	  before	  and	  
early	  after	  challenge	  compared	  to	  gag–env	  and	  control	  groups.	  After	  challenge,	  the	  proliferative	  response	  
was	  maintained	  at	  moderate	  levels	  in	  all	  groups	  until	  the	  end	  of	  the	  experiment.	  
3.2.	  Specific	  antibody	  production	  
Antibody	   titre	   determinations	   using	   a	   whole	   virus	   ELISA	   revealed	   that	   VMV	   antibodies	   were	   not	  
significantly	   produced	   before	   challenge	   in	   any	   of	   the	   groups	   (Fig.	   3A).	   After	   challenge,	   groups	   receiving	  
CD80	  (alone)	  or	  CD80	  and	  CD86	  had	  the	  highest	  antibody	  production	  compared	  to	  the	  control	  group,	  being	  
significantly	  higher	  at	  weeks	  16,	  20	  and	  24	  for	  the	  gag–env–CD80	  group;	  and	  at	  weeks	  16	  and	  20	  for	  the	  
gag–env–CD80–CD86	   group.	   Compared	   with	   the	   gag–env	   group,	   both	   B7	   groups	   also	   had	   significantly	  
higher	   antibody	   titres	   at	   week	   16;	   and	   the	   gag–env–CD80	   group	   had	   increased	   titres	   at	   week	   24.	   In	   all	  
groups,	   the	   antibody	   titre	   increased	   towards	   the	   end	   of	   the	   experimental	   period.	   These	   results	   were	  
confirmed	  with	  a	  commercial	  VMV	  antibody	  ELISA	  test	  (Elitest).	  More	  than	  50%	  of	  the	  vaccinated	  animals	  
became	  seropositive	   (O.D.	   ratios	  >1)	   in	   this	  assay	  after	  challenge	   (by	  week	  16)	   in	  each	  of	   the	   immunized	  
groups,	  whereas	  the	  control	  group	  reached	  this	  percentage	  later	  on	  (week	  20).	  
	  Fig.	  3.	  	  
	  	  	  	  Antibody	  production	  against	  VMV.	  Panel	  A	  shows	  antibody	  titres	  against	  VMV	  as	  detected	  by	  serial	  two-­‐fold	  dilutions	  of	  sera	  from	  sheep	  tested	  
on	  a	  whole	  VMV	  ELISA	  at	  different	  time	  points.	  Sera	  were	  not	  considered	  positive	  unless	  titre	  was	  >100.	  The	  results	  are	  represented	  by	  box	  plots	  
indicating	  the	  median	  value	  and	  the	  interquartile	  range.	  (*)	  Titre	  greater	  than	  the	  control	  group	  (p	  <	  0.05,	  group	  gag–env–CD80	  at	  weeks	  16,	  20	  and	  
24;	  and	  group	  gag–env–CD80–CD86	  at	  weeks	  16	  and	  20);	  (§)	  titre	  greater	  than	  group	  gag–env	  (p	  <	  0.05,	  group	  gag–env–CD80	  at	  weeks	  16	  and	  24;	  
group	  gag–env–CD80–CD86	  at	  week	  16),	   using	  Mann–Whitney	   tests.	   Panel	  B	   shows	  neutralization	   titres	   against	  VMV.	  Different	  dilutions	  of	   the	  
sheep	   serum	   were	   incubated	   with	   the	   virus.	   Neutralizing	   antibody	   titres	   were	   calculated	   as	   the	   reciprocal	   of	   the	   serum	   dilution	   that	   caused	  
neutralization	   in	  50%	  of	  viral	   infectivity	   in	  the	   inoculated	  cultures.	  Median	  and	   interquartile	  range	  are	  represented	   in	  the	  box	  plot.	   (*)	  Statistical	  
differences	  between	  pre-­‐challenge	   and	  post-­‐challenge	  periods	  within	   groups	   (p	   =	   0.046	   for	   gag–env;	   p	   =	   0.043	   for	   gag–env–CD80)	  by	  Wilcoxon	  
tests.	   (§)	   Statistical	   differences	   between	   gag–env–CD80–CD86	   vs.	   gag–env	   and	   gag–env–CD80	   groups	   at	   week	   20	   (p	   =	   0.05	   and	   p	   =	   0.038,	  
respectively),	  using	  Mann–Whitney	  tests.	  
WB	   determinations	   using	  whole	   virus	   antigen	   (not	   shown)	   provided	   information	   on	   antibody	   specificity.	  
Antibodies	   produced	   soon	   after	   challenge	   (by	   week	   16)	   in	   both	   B7	   immunization	   groups	   had	   anti-­‐ENV	  
precursor	   (gp150)	   and	   anti-­‐GAG	   (p25)	   specificities.	   Furthermore,	   most	   of	   the	   B7	   vaccinated	   animals	  
produced	  anti-­‐ENV	  gp44	   transmembrane	   (TM)	  protein	   antibodies,	   but	  only	   at	   late	   stages	   after	   challenge	  
(week	  24).	  Antibodies	  found	  by	  WB	  in	  the	  gag–env	  group	  soon	  after	  challenge	  (weeks	  16	  and	  20)	  were	  only	  
against	  the	  ENV	  precursor,	  anti-­‐GAG	  antibodies	  appearing	  later	  on	  in	  this	  group	  (at	  week	  24).	  The	  control	  
group	  presented	  antibodies	  only	  at	  week	  24,	  having	  then	  anti-­‐ENV	  and	  anti-­‐GAG	  specificities.	  
Regarding	   NtAb	   production	   (Fig.	   3B),	   the	   gag–env–CD80	   and	   the	   gag–env	   vaccinated	   animals	   showed	  
significantly	   increased	   titres	   in	   the	   post-­‐challenge	   (weeks	   16,	   20	   and	   24)	   compared	   to	   the	   pre-­‐challenge	  
period	  (week	  12).	  Interestingly,	  amongst	  the	  immunized	  groups,	  NtAb	  titre	  was	  the	  lowest	  (at	  week	  20)	  in	  
the	  gag–env–CD80–CD86	  group,	  as	  only	  one	  of	  the	  eight	  animals	  within	  this	  group	  had	  NtAb	  at	  this	   time	  
point.	  However,	  this	  difference	  was	  not	  maintained,	  as	  four	  of	  the	  eight	  animals	  became	  NtAb	  positive	  at	  
week	   24.	   Three	   of	   these	   four	   NtAb	   positive	   animals,	   reached	   then	   high	   NtAb	   titres	   and	   were	   provirus	  
positive.	  On	   the	  other	  hand,	  among	   the	   four	  NtAb	  negative	  animals	  of	   this	  group,	  only	  one	  was	  provirus	  
positive	  (see	  Section	  3.3).	  
Overall,	  no	  significant	  antibody	  response	  was	  detected	  in	  groups	  immunized	  with	  B7	  genes	  (CD80	  alone	  or	  
combined	  with	  CD86)	  and	  the	  other	  groups	  upon	  immunization	  and	  booster.	  Although	  after	  challenge	  the	  
B7	  groups	  had	  a	  higher	  antibody	  response	  compared	  to	  the	  control	  group,	  significant	  NtAb	  production	  was	  
detected	  the	  latest	  (week	  24)	  in	  the	  gag–env–CD80–CD86	  immunized	  animals	  and	  only	  in	  50%	  of	  them.	  
3.3.	  Proviral	  load	  after	  challenge	  
Proviral	   load	  was	  measured	  in	  blood	  and	  other	  tissues	  by	  quantitative	  real-­‐time	  PCR	  before	  (to	  verify	  the	  
PCR-­‐negative	   status)	   and	   after	   EV1	   challenge	   (done	   at	  week	   12)	   and	   the	   proportion	   of	   provirus	   positive	  
animals	  determined.	  All	  the	  animals	  were	  free	  of	  provirus	  before	  challenge.	  
In	  blood,	  just	  after	  challenge	  (week	  16),	  all	  groups	  showed	  at	  least	  one	  provirus	  positive	  animal.	  During	  the	  
post-­‐challenge	  period,	  provirus	  was	  detected	  at	   least	  once	   in	  all	   the	  animals	   vaccinated	  with	  gag–env	  or	  
gag–env–CD80	  and	  the	  majority	  of	  animals	  in	  the	  control	  group.	  Significantly,	  only	  50%	  of	  the	  animals	  were	  
provirus	   positive	   in	   the	   gag–env–CD80–CD86	   group	   (	   Table	   2),	   a	   proportion	   that	  was	   significantly	   lower	  
than	  in	  the	  other	  immunized	  groups,	  gag–env–CD80,	  gag–env	  and	  the	  control	  group.	  
	  
Proviral	   load	   was	   also	   determined	   in	   other	   tissues	   (lung	   and	   MLN).	   Viral	   detection	   in	   one	   of	   the	   four	  
analyzed	  pieces	  of	  the	  lung	  or	  in	  the	  MLN	  was	  considered	  indicative	  of	  infection.	  Surprisingly,	  no	  provirus	  
was	  detected	  in	  the	  MLN	  of	  the	  gag–env	  group,	  but	  when	  both	  target	  tissues	  were	  analyzed	  together,	  the	  
gag–env–CD80–CD86	   group	   showed	   again	   the	   lowest	   infection	   level	   with	   only	   25%	   of	   animals	   provirus	  
positive	  (	  Table	  2).	  
When	   analysing	   the	   three	   sampled	   tissues	   together	   (blood,	   lung	   and	  MLN),	   the	   group	   including	   both	  B7	  
genes	   in	   the	   inoculum	   (gag–env–CD80–CD86)	   showed	   a	   significantly	   decreased	   proportion	   of	   provirus	  
positive	  animals	  compared	  with	  the	  other	  groups	  (50%	  vs.	  100%).	  
Proviral	  load	  was	  highly	  variable	  among	  the	  infected	  animals	  in	  all	  the	  groups	  (10–700	  copies).	  There	  were	  
no	  significant	  differences	  between	  groups	  in	  the	  proviral	  load	  amongst	  the	  infected	  animals.	  
3.4.	  Post-­‐mortem	  examination	  
Lung	  and	  MLN	  were	  examined	  at	  necropsy.	  All	   the	  animals	   showed	  macroscopically	  healthy	   lungs.	  Upon	  
microscopic	   examination,	   most	   of	   them,	   including	   those	   of	   the	   gag–env	   and	   control	   groups,	   showed	  
bronchial	  associated	   lymphoid	  tissue	  hyperplasia	   in	   the	  absence	  of	  gross	  clinical	   signs	  such	  as	  congestion	  
and/or	  oedema.	   Follicular	  hyperplasia	  and	   interstitial	  pneumonia	   in	   lungs	  and	   lymphoid	   follicle	   reactivity	  
and	  cortical	  hyperplasia	  in	  MLN	  were	  scored	  jointly,	  as	  described	  elsewhere	  [16],	  to	  determine	  the	  overall	  
histological	   changes.	  The	   results	   showed	  that	  groups	   immunized	  with	  B7	  genes	  had	  a	   significantly	  higher	  
score	   index	  than	  the	  control	  group	   (	  Fig.	  4).	  This	  augmented	  score	  was	  due	  to	  an	   increased	   frequency	  of	  
animals	  in	  these	  groups	  that	  presented:	  (a)	  follicular	  hyperplasia	  in	  lung	  (all	  the	  B7	  immunized	  animals	  vs.	  
70%	  of	  the	  gag–env	  and	  56%	  of	  control	  animals);	  (b)	  a	  mild	  interstitial	  pneumonia	  (62%	  vs.	  50%	  and	  0%	  of	  
the	   animals	   in	   the	   B7	   groups	   compared	   to	   gag–env	   and	   control	   groups,	   respectively);	   and	   (c)	   follicular	  
reactivity	   in	   MLN	   (all	   the	   B7	   immunized	   animals	   vs.	   50%	   of	   the	   gag–env	   and	   70%	   of	   control	   animals).	  
Interestingly,	  perivascular	  infiltrates	  were	  absent	  from	  lungs	  of	  both	  B7-­‐immunized	  groups	  (except	  in	  1	  of	  
the	  16	  animals)	  but	  generally	  present	  in	  the	  control	  and	  gag–env	  groups.	  
	  
Fig.	  4.	  	  
	  	  	  	  Post-­‐mortem	   tissue	   examination.	   The	  mean	  pathology	   score	   ±	   standard	   error	   of	   the	   group	   in	   lung	   and	  mediastinal	   lymph	  node	   is	   shown.	   (*)	  
Pathology	  score	  greater	  than	  the	  control	  group	  (p	  =	  0.021	  for	  gag–env–CD80;	  p	  =	  0.009	  for	  gag–env–CD80–CD86)	  using	  a	  Mann–Whitney	  test.	  
Altogether,	   these	   results	   demonstrate	   an	   increased	   lymphoid	   tissue	   reaction	   and	   the	   absence	   of	   gross	  
clinical	  signs	  in	  target	  organs	  (mild	  lung	  interstitial	  pneumonia	  and	  follicular	  hyperplasia	  in	  lung	  and	  MLN),	  
upon	  B7	  adjuvant	  immunization-­‐intratracheal	  challenge	  with	  VMV.	  
4.	  Discussion	  
Knowing	  that	  CD80	  RNA	  levels	  in	  VMV	  infections	  are	  downregulated	  in	  clinically	  affected	  animals	  [32],	  we	  
investigated	  in	  this	  study	  whether	  the	  use	  of	  ovine	  B7	  genes	  in	  immunizations	  with	  VMV	  gag	  and	  env	  genes	  
enhanced	  specific	  immune	  responses	  in	  sheep	  and	  conferred	  significant	  protection	  after	  challenge	  in	  terms	  
of	  viral	   infection	  and/or	   immune	  enhancement.	  For	  this,	  a	  combined	  vaccination	  strategy	  against	  VMV	  in	  
sheep	   was	   applied,	   consisting	   of	   PMED	   recombinant	   plasmid	   delivery	   [14]	   and	   [15]	   followed	   by	   a	  
subcutaneous	  boost	  with	  recombinant	  MVA	  [15]	  and	  VMV	  challenge.	  This	  allowed	  the	  study	  of	  cellular	  and	  
antibody	  mediated	  immune	  responses	  along	  the	  experimental	  period	  and	  determination	  of	  proviral	  load	  as	  
well	  as	  investigation	  of	  histological	  changes	  at	  necropsy.	  
Early	  CTL/Th1	  responses	  after	  vaccination,	  previously	  studied	  in	  infections	  by	  HIV,	  SIV,	  CAEV	  and	  EIAV,	  have	  
been	  associated	  with	  protection	  in	  individuals	  challenged	  with	  the	  virus	  [41],	  [42],	  [43],	  [44]	  and	  [45].	  Here,	  
the	  earliest	  immune	  responses	  observed	  upon	  vaccination	  were	  mainly	  cellular,	  not	  antibody	  mediated.	  An	  
early	  CTL	  response	  was	  produced	  as	  a	  result	  of	  plasmid	  immunization	  (by	  week	  7)	  in	  both	  B7	  immunization	  
groups,	   being	   then	   significantly	   increased	   in	   the	   group	   receiving	   both	   B7	   genes.	   However,	   the	   response	  
decreased	   after	  MVA	   boost	   (by	   week	   12)	   and	   further	   decreased	   in	   both	   B7	   immunization	   groups,	   until	  
disappearing	   in	   the	   group	   receiving	   both	   CD80	   and	   CD86	   after	   challenge.	   In	   contrast,	   the	   proportion	   of	  
precursor	   CTL-­‐positive	   animals	   had	   a	   tendency	   to	   increase	   in	   the	   control	   group	   in	   the	   post-­‐challenge	  
period.	  In	  a	  previous	  vaccination-­‐challenge	  study,	  using	  the	  same	  gag–env	  immunization	  approach	  without	  
including	  B7	  genes	   in	  the	   inoculum,	  no	  CTL-­‐positive	  animals	  were	  found	  by	  week	  7,	  rather	  CTL	  responses	  
appeared	  later,	  after	  MVA	  boosting,	  and	  became	  significantly	  higher	  compared	  to	  unvaccinated	  controls	  by	  
week	  20	   (	   [15]	  and	   this	   study).	  Also,	  with	  a	  gag–env	  mucosal	   immunization	  approach,	  a	   very	   limited	  CTL	  
response	   was	   obtained	   upon	   immunization	   and	   challenge	   [16].	   Altogether,	   these	   observations	   strongly	  
suggest	  that	  inclusion	  of	  B7,	  and	  particularly	  both	  B7	  genes	  (CD80	  and	  CD86)	  in	  the	  immunization	  inoculum	  
leads	   to	   an	   early	   (week	   7)	   significant	   production	   of	   CTL	   precursors.	   Likely,	   these	   cells	   underwent	   clonal	  
expansion	  and	  re-­‐distribution	  in	  the	  organism	  (week	  12)	  and	  were	  maintained	  in	  a	  low	  proportion	  in	  blood	  
after	  virus	  clearance	  (weeks	  16,	  20	  and	  24).	  The	  enhancement	  of	  CTL	  responses	  when	  incorporating	  CD86	  
into	   the	   vaccine	   is	   in	   agreement	  with	   a	   series	   of	   previous	  HIV	   studies	   in	  mice	   [46],	   [47]	   and	   [48]	  where	  
inclusion	  of	  CD80	  in	  the	  inoculum	  did	  not	  generate	  CTL	  responses.	  However,	  the	  relative	  role	  of	  both	  CD80	  
and	   CD86	   molecules	   remains	   controversial,	   as	   there	   are	   studies	   in	   mice	   which	   either	   propose	   the	  
enhancement	  of	  both	  cellular	  and	  humoral	  responses	  when	  using	  CD86	  [49]	  or	  describe	  the	  enhancement	  
of	  CTL	  responses	  when	  incorporating	  CD80	  rather	  than	  CD86	  [50].	  
Like	   CTL	   production,	   significantly	   increased	   proliferative	   responses	   against	   a	  GAG	  protein	  were	   found	   as	  
early	   as	   week	   7	   (upon	   plasmid	   immunization),	   but	   only	   in	   the	   group	   immunized	   with	   both	   B7	   genes,	  
compared	   to	   unvaccinated	   controls.	   Upon	   MVA	   boosting	   (week	   10),	   proliferative	   responses	   became	  
significantly	   increased	  in	  both	  groups	  receiving	  B7	  genes.	  Using	  the	  same	  immunization	  protocol	   in	  sheep	  
immunized	  with	  gag–env	  (without	  including	  B7),	  the	  proliferative	  response	  against	  a	  GAG	  protein	  was	  also	  
found	  by	  weeks	  7	  and	  12	  [15].	  Following	  challenge	  (performed	  at	  week	  12),	  proliferative	  responses	  against	  
GAG	  proteins	  were	  significantly	   increased	  compared	   to	  controls	   (week	  16)	   in	  both	  studies	   (	   [15]	  and	   this	  
study)	  and	   in	  work	   involving	  sheep	  mucosal	  gag–env	   immunization	   [16].	  Similarly	   to	   this	  work,	  a	  gag–pol	  
plasmid	   immunization	   study	   in	   chimpanzees	   demonstrated	   that	   inclusion	   of	   CD86	   gene	   in	   the	   inoculum	  
augmented	  the	  viral-­‐antigen-­‐specific	   lymphoproliferative	  responses	  [51].	  Overall,	   this	  study	  demonstrates	  
that	   inclusion	   of	   B7	   genes	   (especially	   if	   both	   genes	   are	   combined)	   in	   gag–env	   immunization	   results	   in	  
increased	  early	  lymphocyte	  proliferative	  responses,	  and	  strongly	  suggests	  that	  some	  of	  these	  lymphocytes	  
may	   be	   involved	   in	   CTL	   activation.	   The	   group	   receiving	   both	   B7	   genes	   had	   a	   decreased	   proportion	   of	  
provirus	  positive	  animals	  and	  a	  significantly	   increased	  early	  CTL	  and	  proliferative	  responses	  after	  plasmid	  
immunization,	   leading	   to	   a	   high	   clonal	   expansion	   and	   strong	   memory	   cell	   production	   by	   the	   time	   of	  
challenge.	  Similarly,	  in	  an	  in	  vitro	  study	  a	  role	  for	  CD86	  rather	  than	  CD80	  in	  suppression	  of	  HIV	  replication	  
has	  been	  linked	  to	  enhanced	  CD8+	  cell	  activity	  [52].	  
Antibody	  (IgG),	  as	  detected	  by	  ELISA,	  was	  not	  produced	  upon	  plasmid	  or	  MVA	  immunization	  in	  any	  of	  the	  
immunization	   groups,	  which	   is	   in	   agreement	  with	   previous	   VMV	   plasmid	   immunization	   studies	   in	   sheep	  
[14]	  and	  [16],	  and	  with	  work	  in	  mice	  on	  immunization	  with	  HIV	  plasmids	  in	  the	  presence	  of	  CD80	  or	  CD86	  
genes	  [49].	  Just	  after	  challenge	  (week	  16)	  and	  until	  the	  end	  of	  the	  experimental	  period,	  groups	  receiving	  B7	  
genes	  produced	  both	  anti-­‐ENV	  and	  anti-­‐GAG	  antibodies,	  as	   revealed	  by	  WB,	  whereas	   the	  gag–env	  group	  
had	  anti-­‐ENV	  but	  a	  very	  low	  production	  of	  anti-­‐GAG	  antibodies	  at	  weeks	  16	  and	  20	  and	  the	  control	  group	  
did	  not	  show	  either	  anti-­‐ENV	  or	  anti-­‐GAG	  antibodies	  until	  week	  20.	  In	  natural	  infections,	  anti-­‐ENV	  and	  GAG	  
p25	  antibodies	  are	  usually	  produced	   the	  earliest	   [53]	  although	   there	  can	  be	  a	  delay	   in	   the	  production	  of	  
anti-­‐ENV	  antibodies	  [54].	  In	  this	  work,	  the	  delay	  was	  restricted	  to	  TM-­‐ENV	  antibodies,	  likely	  because	  some	  
TM	  epitopes	  are	  less	  exposed.	  The	  presence	  of	  ENV-­‐	  and	  particularly	  GAG-­‐specific	  antibodies	  in	  both	  of	  the	  
B7	   immunized	   groups	   early	   after	   challenge	   could	   be	   due	   to	   increased	   costimulatory	   signals	   and	   pre-­‐
activation	  of	  the	  B	  cells	  as	  a	  result	  of	  immunization	  (weeks	  7	  and	  12)	  in	  these	  groups.	  
NtAb	   production	   was	   very	   limited	   in	   this	   study,	   increasing	   in	   all	   the	   groups	   towards	   the	   end	   of	   the	  
experimental	  period.	  The	  delay	   in	  NtAb	  production	  observed	   in	  the	  group	  receiving	  both	  B7	  genes	  (CD80	  
and	  CD86)	  may	  be	   related	   to	  a	  decreased	  viral	   exposure	   in	   this	   group	  after	   challenge,	  with	  only	  50%	  vs.	  
100%	   of	   provirus	   positive	   animals.	   Also	   the	   probability	   of	   finding	   NtAb	   was	   decreased	   in	   provirus-­‐free	  
animals	  of	  this	  immunization	  group	  by	  week	  24.	  A	  similar	  association	  between	  the	  lack	  of	  NtAb	  production	  
and	   decreased	   viral	   load/exposure	   has	   been	   found	   in	   vaccinated	   animals	   of	   a	   previous	   VMV	   env-­‐based	  
immunization-­‐challenge	   study	   [14].	   Furthermore,	  NtAb	  have	  been	   found	   in	  VMV	  vaccinated	  animals	   that	  
become	   infected	   after	   challenge	   [20].	   NtAb	   were	   detected	   post-­‐challenge	   in	   this	   study,	   and	   not	   in	   our	  
previous	  immunization	  study	  performed	  under	  the	  same	  experimental	  conditions	  but	  in	  the	  absence	  of	  B7	  
adjuvants	  [15].	  This	  was	  most	  likely	  due	  to	  differences	  in	  the	  sensitivity	  of	  the	  neutralization	  assay	  used	  in	  
both	  studies,	  as	  here	  its	  readout	  was	  viral	  replication	  (using	  a	  β-­‐galactosidase	  construct)	  whilst	  Niesalla	  et	  
al.	  [15]	  detected	  syncytium	  formation.	  
An	   early,	   strong	  NtAb	   response	  has	   been	   linked	   to	   reduced	  CNS	  pathology	   after	   infection	  of	   sheep	  with	  
VMV	   [55],	   and	   neutralization	   escape	   mutants	   do	   arise	   in	   persistently	   infected	   animals	   [56]	   and	   [57].	  
However,	  there	  is	  mounting	  evidence	  that	  neutralization	  by	  antibody	  may	  not	  be	  important	  in	  controlling	  
SRLV	   infections	   [58]	  and	   [59].	   Likely,	   some	  of	   the	  NtAb	  detected	   in	  vitro	  are	   inefficient	   in	  controlling	   the	  
infection	   in	   vivo.	   On	   the	   other	   hand,	   in	   the	   immunodeficiency	   virus	   field,	   antibodies	   functioning	   in	  
antibody-­‐dependent	   cellular	   cytotoxicity	   (ADCC)	   responses	   may	   be	   important	   in	   controlling	   virus	   (SHIV)	  
replication	  [58].	  As	  VMV	  is	  primarily	  cell	  associated	  in	  vivo,	  ADCC	  may	  be	  a	  particularly	  important	  antibody	  
effector	   function.	  However,	   IgG2	  antibody	   involved	   in	  ADCC,	   is	  not	   induced	  after	  VMV	   infection	   [36]	  and	  
[60]	   and	   induction	   of	   this	   isotype	   by	   vaccination	   may	   provide	   a	   significant	   mode	   of	   protection.	   Future	  
studies	   to	   determine	   which	   antibody	   isotypes	   and	   which	   cellular	   and	   cytokine	   profiles	   are	   induced	   by	  
prime-­‐boost	  vaccination	  regimens	  are	  needed.	  
Significantly,	   PMED	   immunization	   using	   VMV	   gag	   and	   env	   genes,	   together	   with	   B7	   genes	   combined,	  
triggered	  significantly	   increased	  early	   specific	  CTL	  and	  proliferative	   responses,	   leading	   to	   the	  presence	  of	  
precursor	  and	  effector	  memory	  T	  cells.	  These	  cells	  could	  be	  present	  in	  the	  lung	  and	  the	  MLN,	  having	  local	  
follicular	   hyperplasia	   (both)	   and	   a	   mild	   interstitial	   pneumonia	   (lung)	   upon	   intratracheal	   challenge,	   as	  
observed	  at	  necropsy.	  An	  increased	  reaction	  score	  in	  target	  tissues	  (lesion)	  was	  also	  observed	  in	  a	  previous	  
study	   on	   immunization	   with	   the	   combination	   of	   the	   gag	   and	   env	   genes	   [15].	   However,	   all	   the	   animals	  
receiving	  B7	  had	  overall	  mild	   lesions/inflammatory	  signs.	  There	  was	  no	  disappearance	  of	  epithelial	   tissue	  
and	   the	   lesions	   (presence	   of	   lymphocytes,	   follicular	   hyperplasia,	   etc.)	   would	   be	   those	   expected	   from	   a	  
transient	   antigen	   exposure.	   None	   of	   the	   animals	   had	   clinical	   signs,	   macroscopic	   or	   strong	   microscopic	  
lesions,	   that	  might	   be	   considered	   irreversible.	   These	   tissue	   changes,	   observed	   at	   the	   third	  month	   post-­‐
challenge	   (this	   work	   and	   previous	   studies;	   [15]	   and	   [16]),	   might	   disappear	   when	   prolonging	   the	   post-­‐
challenge	  period	  for	  about	  one	  year,	  as	  observed	  in	  previous	  work	  employing	  the	  same	  viral	  dose	  and	  strain	  
for	  challenge	  [14].	  
The	   fate	   of	   lesions	   may	   be	   linked	   to	   the	   presence/absence	   of	   infection.	   In	   this	   regard,	   a	   significant	  
proportion	  (50%)	  of	  animals	  in	  the	  group	  receiving	  both	  B7	  genes	  was	  provirus	  negative	  while	  showing	  mild	  
lesions,	  but	  in	  these	  animals,	  the	  immunization	  could	  have	  just	  delayed	  the	  appearance	  of	  infection.	  If	  so,	  
virus-­‐associated	  clinical	  disease	  would	  be	  expected	  to	  take	  more	  that	  one	  year	  to	  appear	  [14],	  taking	  into	  
account	  the	  challenge	  dose	  used	  and	  the	  prolonged	  period	  often	  required	  in	  lentiviral	  infections	  for	  target	  
organs	   to	  present	   severe	   lesions.	  Alternatively,	   these	  animals	   could	  have	  been	   really	  protected	   from	   the	  
viral	   infection.	   In	   this	   case,	   a	   progressive	   disappearance	   of	   the	   interstitial	   pneumonia	   and	   of	   follicular	  
hyperplasia	  would	  be	  expected	  as	  antigen	  exposure	  would	  be	  missing.	   In	  any	  case,	  the	   immune	  response	  
was	  able	  to	  either	  eliminate	  the	  virus	  or	  delay	  the	  establishment	  of	   infection	   in	  these	  animals	  during	  the	  
experimental	  period.	  To	  distinguish	  between	  these	  alternatives,	  cell	  and	  cytokine	  profile	  determinations	  in	  
target	  tissues/organs	  would	  be	  relevant	  again	  in	  longer	  term	  post-­‐challenge	  studies.	  These	  will	  also	  help	  to	  
understand	   why	   the	   sensitization	   before	   challenge	   eventually	   enhances	   or	   stops	   the	   lesion	   in	   these	  
animals.	  
In	   conclusion,	   in	   VMV	   gag–env	   vaccination,	   the	   use	   of	   B7	   genes	   particularly	   in	   combination	   (CD80	   and	  
CD86),	   induces	   early	   increased	   cellular	   responses	   (CTL	   and	   proliferative)	   before	   challenge	   as	   well	   as	  
antibody	   responses	   to	   viral	   antigens	   soon	   after	   challenge	   and	   enhances	   protective	   effects	   against	   early	  
infection	  while	  triggering	  an	  immune	  reaction	  of	   lymphoid	  tissue	  in	  challenged-­‐target	  organs.	  Overall,	  the	  
use	  of	  B7	  genes	  combined	  results	  in	  decreased	  infection,	  but	  new	  strategies	  need	  to	  be	  explored	  in	  order	  to	  
further	   increase	   the	   proportion	   of	   provirus-­‐free	   healthy	   animals	   in	   long	   term	   immunization-­‐challenge	  
approaches	  and	  determine	  the	  final	  outcome	  and	  profile	  of	  the	  inflammatory	  reactions	  in	  target	  organs	  and	  
related	  tissues.	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